Dr Ariane Lewis discusses how we can navigate uncertainty and ambiguity about brain death by understanding clinical criteria for brain death determination and how our approaches to death are culturally and socially situated.
Pablo A. Ormachea, JD, Sasha Davenport, Gabe Haarsma, PhD, Anna Jarman, Howard Henderson, PhD, and David M. Eagleman, PhD
A new neuropsychological, game-based test battery to measure traits predictive of recidivism holds promise for individually tailoring criminal sentences.
AMA J Ethics. 2016; 18(3):243-251. doi:
10.1001/journalofethics.2016.18.3.stas1-1603.
Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021; 23(5):E405-409. doi:
10.1001/amajethics.2021.405.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Priorities far beyond generating morbidity or mortality data are needed to improve patients’ experiences, innovate metrics, and advance surgical palliation as a field.
AMA J Ethics. 2021; 23(10):E806-810. doi:
10.1001/amajethics.2021.806.